Antidepressants and hyperprolactinaemia
- selective serotonin reuptake inhibitors (SSRIs) are a common cause of drug-induced hyperprolactinaemia
- SSRIs are associated with an approximate eight-fold increased risk of development of galactorrhoea compared with other antidepressants
- SSRIs are associated with an approximate eight-fold increased risk of development of galactorrhoea compared with other antidepressants
- also delayed orgasm or ejaculation is a possible adverse effect in men treated with SSRIs
- monoamine oxidase inhibitors and tricyclic antidepressants have also been rarely reported to cause galactorrhoea or hyperprolactinaemia
Sexual dysfunction and SSRIs
- sexual dysfunction occurs through several brain pathways involving increases in serotonin (5-HT), decreases in dopamine (DA) and inhibition of nitric oxide synthase
- increases in cortico-limbic 5-HT result in decreased sexual desire, ejaculation and orgasm selective serotonin reuptake inhibitor (SSRI)-induced sexual dysfunction occurs in 30%-80% of patients and is a main cause of treatment discontinuation
- increases in cortico-limbic 5-HT result in decreased sexual desire, ejaculation and orgasm selective serotonin reuptake inhibitor (SSRI)-induced sexual dysfunction occurs in 30%-80% of patients and is a main cause of treatment discontinuation
- management
- check PRL - SSRIs can cause drug-induced hyperprolactinaemia
- seek expert advice
- pharmacologic methods to reduce sexual dysfunction involve dose reduction, augmentation, or switching medication
- since dose reduction is the least disruptive strategy it should be considered first, particularly in a responder (1)
- altering 5-HT receptor antagonism and agonism can have favourable sexual effects, but may cause other adverse event
- mirtazapine antagonizes 5-HT2 and 5-HT3 receptors and it has been successfully used as an add-on therapy for antidepressant-induced sexual dysfunction
- however associated with a relatively high rate of weight gain
- other possible augmentation therapies that have been used include cyproheptidine and buspirone
- mirtazapine antagonizes 5-HT2 and 5-HT3 receptors and it has been successfully used as an add-on therapy for antidepressant-induced sexual dysfunction
- phospho-diesterase inhibitors e.g. sildenafil have demonstrated evidence for the reversal of SSRI-induced sexual side effects in men
- DA release enhances sexual function
- evidence supports adjunctive bupropion XL for reversing SSRI-induced sexual dysfunction in men and women across the domains of desire, arousal and orgasm
- evidence supports adjunctive bupropion XL for reversing SSRI-induced sexual dysfunction in men and women across the domains of desire, arousal and orgasm
- several antidepressants, including bupropion, moclobemide, and mirtazapine have little to no effect on sexual function compared with placebo when used as a monotherapy
- evidence suggests exercise can improve sexual function in SSRI-induced sexual dysfunction
- since dose reduction is the least disruptive strategy it should be considered first, particularly in a responder (1)
- check PRL - SSRIs can cause drug-induced hyperprolactinaemia
Reference:
- Rizvi SJ1, Kennedy SH.Management strategies for SSRI-induced sexual dysfunction. J Psychiatry Neurosci. 2013 Sep;38(5):E27-8.
Related pages
Create an account to add page annotations
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.